The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi will explore additional indications for gusacitinib in a Phase I study.

Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

From personal setbacks to professional leadership, McDowell advocates for smarter wound care and stronger ethics in medicine. NASHVILLE, TN / ACCESS Newswire / June 24, 2025 / In a recent exclusive ...

This was the stock's third consecutive day of gains.

NEW YORK, NY, USA I June 23, 2025 I Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary ...